Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Neuro-Oncology|2014Cited by 147
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Giles Robinson et al.|Neuro-Oncology|2022Cited by 136
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Yaël P. Mossé et al.|Clinical Cancer Research|2018Cited by 88
Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Pediatric Blood & Cancer|2013Cited by 87
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61